{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=69",
    "query": {
      "condition": "DNA",
      "page": 69
    },
    "page_size": 10
  },
  "pagination": {
    "page": 69,
    "page_size": 10,
    "total_count": 3221,
    "total_pages": 323,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=70&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=68&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T04:34:44.955Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05672927",
      "title": "Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Immunization",
        "HPV Infection",
        "Human Papillomavirus"
      ],
      "interventions": [
        {
          "name": "9-valent HPV vaccine, 2 doses alternate timing",
          "type": "BIOLOGICAL"
        },
        {
          "name": "9-valent HPV vaccine, 3 doses standard timing",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "27 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "27 Years to 45 Years · Female only"
      },
      "enrollment_count": 618,
      "start_date": "2023-01-18",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05672927"
    },
    {
      "nct_id": "NCT00787761",
      "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Disorders",
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "nonmyeloablative allogeneic HSCT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Northside Hospital, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2007-04",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2012-10-01",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00787761"
    },
    {
      "nct_id": "NCT00101205",
      "title": "Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Angioimmunoblastic T-cell Lymphoma",
        "B-cell Childhood Acute Lymphoblastic Leukemia",
        "B-cell Chronic Lymphocytic Leukemia",
        "Childhood Burkitt Lymphoma",
        "Childhood Diffuse Large Cell Lymphoma",
        "Childhood Grade III Lymphomatoid Granulomatosis",
        "Childhood Immunoblastic Large Cell Lymphoma",
        "Childhood Nasal Type Extranodal NK/T-cell Lymphoma",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Noncutaneous Extranodal Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Anaplastic Large Cell Lymphoma",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Small Intestine Lymphoma",
        "T-cell Childhood Acute Lymphoblastic Leukemia",
        "T-cell Large Granular Lymphocyte Leukemia",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 40,
      "start_date": "2004-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-02-24",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101205"
    },
    {
      "nct_id": "NCT05692505",
      "title": "Multicenter Performance Study of QuadQuik Invitro Diagnostic Device",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections",
        "Hepatitis C",
        "Hepatitis B",
        "Syphilis Infection"
      ],
      "interventions": [
        {
          "name": "QuadQuik",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Genlantis Diagnostics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2023-04-01",
      "completion_date": "2023-06-01",
      "has_results": false,
      "last_update_posted_date": "2023-01-20",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05692505"
    },
    {
      "nct_id": "NCT03631641",
      "title": "Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Adenoma",
        "Colon Carcinoma",
        "Lynch Syndrome",
        "MLH1 Gene Mutation",
        "MSH2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "John Hays",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2018-10-04",
      "completion_date": "2021-01-25",
      "has_results": true,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03631641"
    },
    {
      "nct_id": "NCT00002153",
      "title": "Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma, Kaposi",
        "HIV Infections",
        "Lymphoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "A-007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DEKK-TEC, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 25,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002153"
    },
    {
      "nct_id": "NCT00410202",
      "title": "Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B, Chronic"
      ],
      "interventions": [
        {
          "name": "Entecavir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir",
          "type": "DRUG"
        },
        {
          "name": "Adefovir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 629,
      "start_date": "2008-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2013-11-21",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 1,
      "location_summary": "Farmington, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00410202"
    },
    {
      "nct_id": "NCT04013802",
      "title": "TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Viral Infection"
      ],
      "interventions": [
        {
          "name": "HLA-matched VSTs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 47,
      "start_date": "2021-03-08",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04013802"
    },
    {
      "nct_id": "NCT02581410",
      "title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 430,
      "start_date": "2015-12-15",
      "completion_date": "2017-08-01",
      "has_results": true,
      "last_update_posted_date": "2018-08-28",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 32,
      "location_summary": "Huntsville, Alabama • Daly City, California • Los Gatos, California + 27 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02581410"
    },
    {
      "nct_id": "NCT06855160",
      "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chickenpox"
      ],
      "interventions": [
        {
          "name": "Candidate varicella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Marketed varicella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV (pneumococcal conjugate vaccine) 13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV 20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxneuvance",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 911,
      "start_date": "2025-04-17",
      "completion_date": "2027-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-11-07T04:34:44.955Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06855160"
    }
  ]
}